The C4C consortium yesterday announced the implementation of France's first ever dedicated technical facility for the manufacture of cell therapy products.
The C4C project (coordinated by CELLforCURE, a subsidiary of the leading French biopharmaceutical company LFB Biotechnologies, brings together the skills of two biotech companies (Celogos and CleanCells) and seven public-sector organizations and university medical centers (the French Blood Agency's [Etablissement Francais du Sang, EFS] directorates in the Aquitaine-Limousin and Pyrenees-Mediterranee regions of France, Bordeaux University Medical Center [CHU de Bordeaux], Lille University Medical Center/University of Lille 2 [CHU de Lille], Nantes University Medical Center, [CHU de Nantes] and the Biological Resource Center at Lyons University Medical Center [Banque de Tissus et de Cellules des Hospices Civils de Lyon].
The first five products are currently being developed, with a view to validating the facility dedicated to the routine production of clinical trial and therapeutic batches. This facility is located on LFB's site in Les Ulis, close to Paris.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze